Answers are grounded in this paper and cite their sources.
Mutations in RNA-binding proteins, including fused in sarcoma (FUS) and TAR DNA-binding protein 43 (TDP-43, encoded by TARDBP), are associated with sporadic and familial amyotrophic lateral sclerosis. A major question is whether neuronal loss is caused by toxic gain-of-function cytoplasmic aggregates or loss of nuclear RNA-binding protein function. We generated a transgenic mouse overexpressing exogenous FUS without a nuclear localization signal (ΔNLS-FUS), which developed progressive spastic motor deficits and neuronal loss in the motor cortex. The ΔNLS-FUS protein was restricted to the cytoplasm and formed ubiquitin/p62-positive aggregates. Endogenous FUS expression, nuclear localization, and splicing activity were not altered, indicating that mislocated FUS is sufficient for proteinopathy. Crossing ΔNLS-FUS with wild-type human TDP-43 transgenic mice exacerbated pathological and behavioural phenotypes, suggesting that both proteins are involved in a common cascade. RNA-sequence analysis revealed specific transcriptome alterations, including genes regulating dynein-associated molecules and endoplasmic reticulum stress. ΔNLS-FUS mice are promising tools for understanding amyotrophic lateral sclerosis pathogenesis and testing new therapeutic approaches. ‘Fused in sarcoma’ (FUS) mutations are associated with ALS. Shiihashi et al. generate a mouse model that overexpresses FUS without a nuclear localization signal (ΔNLS-FUS) and shows progressive motor deficits. ΔNLS-FUS forms cytoplasmic aggregates, whereas endogenous FUS is unaffected. Mislocation of FUS is thus sufficient for a gain-of-function ALS phenotype.
No takes yet. Share an insight, caveat, or question.
Shiihashi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: